← Back to Search

MK-1942 15 mg for Alzheimer's Disease

Phase 2
Waitlist Available
Research Sponsored by Merck Sharp & Dohme LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to ~ 14 weeks
Awards & highlights

Study Summary

This trial tests a new drug to treat mild to moderate Alzheimer's Disease and assess its safety and effectiveness.

Eligible Conditions
  • Alzheimer's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to ~ 14 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to ~ 14 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Alzheimer's Disease
Number of Participants Discontinuing Study Medication due to an Adverse Event
Number of Participants Experiencing an Adverse Event (AE)
Secondary outcome measures
Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) Overall Score at Week 12
Mean Change From Baseline in The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Total Score at Week 12

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: MK-1942 5 mgExperimental Treatment1 Intervention
Participants will receive a single 5 mg MK-1942 capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
Group II: MK-1942 15 mgExperimental Treatment1 Intervention
Participants will receive a single 8 mg MK-1942 capsule twice daily (BID), taken orally for one week. Then the dose is titrated up to 15 mg MK-1942 capsule twice daily (BID), taken orally for up to 11 weeks.
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive a placebo capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MK-1942
2021
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCLead Sponsor
3,886 Previous Clinical Trials
5,054,472 Total Patients Enrolled
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,777 Previous Clinical Trials
8,063,381 Total Patients Enrolled

Media Library

MK-1942 15 mg Clinical Trial Eligibility Overview. Trial Name: NCT05602727 — Phase 2
Alzheimer's Disease Research Study Groups: Placebo, MK-1942 15 mg, MK-1942 5 mg
Alzheimer's Disease Clinical Trial 2023: MK-1942 15 mg Highlights & Side Effects. Trial Name: NCT05602727 — Phase 2
MK-1942 15 mg 2023 Treatment Timeline for Medical Study. Trial Name: NCT05602727 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit for this research study over or under 35 years?

"The parameters for enrollment in this medical trial stipulate that the minimum age of participants is 55 and no participant can be over 90 years old."

Answered by AI

Does this scientific investigation have any openings for participants?

"This clinical trial, which was made public on December 2nd 2022 and last revised on the 9th of that same month, is actively searching for patients."

Answered by AI

Has the FDA sanctioned MK-1942 15 mg for therapeutic use?

"Our team has assigned a score of 2 to MK-1942 15 mg, as this is only in the second stage of clinical trials and there is limited evidence for its efficacy. However, it does have some data that supports its safety profile."

Answered by AI

In how many distinct locations is this research endeavor being conducted?

"There are 4 active recruiting sites, including the JEM Research Institute in Atlantis, Velocity Clinical Research of Hallandale Beach, and Advanced Memory Research Institute of New jersey located in Toms River."

Answered by AI

How many participants has this study recruited thus far?

"In order to complete this medical trial, the sponsor Merck Sharp & Dohme LLC is actively recruiting 408 participants that meet the inclusion criteria. The investigation will be conducted across multiple sites, including JEM Research Institute in Atlantis, Florida and Velocity Clinical Research in Hallandale Beach, New jersey."

Answered by AI

To what extent is enrollment in this research available?

"Currently, this research endeavour is seeking 408 people with Alzheimer's disease between the ages of 55 and 90. The criteria for enrollment necessitates that a participant must be diagnosed with mild to moderate AD dementia according to NINCDS-ADRDA rules, possess a Mini Mental State Examination (MMSE) score within 12 and 22 points inclusively, maintain constant acetylcholinesterase inhibitor (AChEI) therapy at stable doses preceding administration of study intervention until its completion, as well as have an official study partner who can provide information on their functional capabilities, work/educational background, cognitive performance emotional state etcetera"

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
2022. "Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05602727.
~42 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top